Abstract:The TALE-based nucleases (TALENs) and transcript factors (TALE-TFs) have been used for genome editing and targeting endogenous gene regulation.Moreover,TALE proteins can be modified to activate gene expression by targeting its enhancer.However,the optimal length of TALE N-terminus that may affect the cleavage efficiency of TALENs is uncertain.In this study,we design N-terminal targeting strategy to achieve higher cleavage efficiency by optimizing the length of N-terminus using our reporter systems in both yeast and mammalian cell lines.For this purpose we first constructed a series of truncated mutants in the N-terminal sequences of TALENs expression plasmids,and yeast and mammalian reporter systems,respectively.Gene transfer and activation efficiency analyses showed that the truncated sequence with 120 N-terminal residues produced the highest efficiency in yeast AH109 cells,while that of 153 N-terminal residues gave the highest efficiency in 293T cells,but no significant difference in the efficiency among the 153,140 and 160 N-terminal residues (P ＞ 0.05).Subsequently,we used the optimized N-terminal structure for TALE-TF to activate the stringently silenced pluripotent gene Oct4 in mouse embryonic fibroblasts (MEFs),where the expression of the endogenous Oct4 gene that plays a crucial role in the generation of induced pluripotent stem cells (iPSCs) from somatic cells was enhanced up to 418-fold,compared with the negative control.Our results suggest that the length of the N-terminal sequence of TALEN required for its optimal function is different between yeast and mammalian cells.Our data also provide an optimization strategy by modifying the TALE-TF to induce endogenous gene expression at high levels,which is perhaps significant for generation of iPS cells from somatic cells.

Precise Gene Modification Mediated by TALEN and Single-Stranded Oligodeoxynucleotides in Human Cells.

[Applications of ZFN, TALEN and CRISPR/Cas9 Techniques in Disease Modeling and Gene Therapy].

Utilization of TALEN and CRISPR/Cas9 Technologies for Gene Targeting and Modification

Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification.

Genome Editing of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells with Zinc Finger Nucleases for Cellular Imaging.

Various applications of TALEN- and CRISPR/Cas9-mediated homologous recombination to modify the Drosophila genome.

Efficient Gene Editing in Pluripotent Stem Cells by Bacterial Injection of Transcription Activator-Like Effector Nuclease Proteins

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease.

Talen or Cas9-Rapid, Efficient and Specific Choices for Genome Modifications

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

A Talen-Based Strategy For Efficient Bi-Allelic Mirna Ablation In Human Cells

Applications of Genome Editing Technology in the Targeted Therapy of Human Diseases:Mechanisms,advances and Prospects

Crispr-Based Editing of Human Pluripotent Stem Cells for Disease Modeling

Bacterial delivery of TALEN proteins for human genome editing.

An Efficient Method to Induce Endogenous Oct4 Expression in MEF Cells by Optimized Design of TALE-TF

High-Efficiency And Heritable Gene Targeting In Mouse By Transcription Activator-Like Effector Nucleases

HLA DR Genome Editing with TALENs in Human iPSCs Produced Immune-Tolerant Dendritic Cells

Transcription Activator‐like Effector Nucleases (talens): A Highly Efficient and Versatile Tool for Genome Editing

Direct Activation of Human and Mouse Oct4 Genes Using Engineered TALE and Cas9 Transcription Factors.

High-Level Precise Knockin of Ipscs by Simultaneous Reprogramming and Genome Editing of Human Peripheral Blood Mononuclear Cells.